Summary of the NACI Statement on the Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease
Background: Trumenba™, a bivalent, factor-H binding protein meningococcal serogroup B (MenB-fHBP) vaccine was authorized for use in Canada in October 2017 for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in individuals 10–25 years of age. The Na...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Health Agency of Canada
2020-02-01
|
| Series: | Canada Communicable Disease Report |
| Subjects: | |
| Online Access: | https://doi.org/10.14745/ccdr.v46i23a03 |
| _version_ | 1818759496427634688 |
|---|---|
| author | Robyn Harrison Robert Stirling Oliver Baclic Wendy Vaudry |
| author_facet | Robyn Harrison Robert Stirling Oliver Baclic Wendy Vaudry |
| author_sort | Robyn Harrison |
| collection | DOAJ |
| description | Background: Trumenba™, a bivalent, factor-H binding protein meningococcal serogroup B (MenB-fHBP) vaccine was authorized for use in Canada in October 2017 for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in individuals 10–25 years of age. The National Advisory Committee on Immunization (NACI) provides recommendations regarding the use of meningococcal vaccines to the Public Health Agency of Canada.
Objective: To summarize NACI recommendations regarding the use of MenB-fHBP vaccine in Canada.
Methods: The NACI Meningococcal Disease Working Group developed a predefined search strategy to identify all eligible studies, assessed the quality of these studies, and summarized and analyzed the findings. According to the NACI evidence-based process, the working group then proposed recommendations and identified the grade of evidence that supported them. In light of the evidence, the recommendations were then considered and approved by NACI.
Results: The two serogroup B meningococcal vaccines currently authorized for use in Canada are not interchangeable as they contain different antigens and there are no published studies on the immunogenicity resulting from a vaccination series combining the two products. Following the review of evidence, NACI recommends that MenB-fHBP vaccine may be considered as an option for use in individuals 10 years of age and older in situations when a serogroup B meningococcal vaccine should be offered: 1) during serogroup B meningococcal disease outbreaks or with the emergence of hyperendemic N. meningitidis strains that are predicted to be susceptible to the vaccine; 2) for individuals who are close contacts with a case of invasive meningococcal disease caused by serogroup B N. meningitidis; 3) for individuals with underlying medical conditions that would put them at higher risk of meningococcal disease than the general population; or 4) for individuals at higher risk of exposure to serogroup B meningococcal isolates than the general population. NACI also recommends that MenB-fHBP vaccine may be considered as an option for individuals 10–25 years of age who are not at higher risk of meningococcal disease than the general population, but who wish to reduce their risk of invasive serogroup B meningococcal disease.
Conclusion: NACI recommends immunization against serogroup B IMD for all individuals who are at a higher risk of disease due to an underlying medical condition or an increased risk of exposure. In addition to providing guidance to public health decision-makers (i.e. provinces/territories making decisions for publicly-funded immunization programs), these NACI recommendations provide information to individuals, vaccine providers and organizations about vaccines that may not currently be included in publicly funded immunization programs. NACI continues to recommend against the use of the serogroup B vaccines in routine universal immunization programs in Canada at this time. |
| first_indexed | 2024-12-18T06:43:39Z |
| format | Article |
| id | doaj.art-5266f7573ba64d58a50f47f65153fc25 |
| institution | Directory Open Access Journal |
| issn | 1481-8531 |
| language | English |
| last_indexed | 2024-12-18T06:43:39Z |
| publishDate | 2020-02-01 |
| publisher | Public Health Agency of Canada |
| record_format | Article |
| series | Canada Communicable Disease Report |
| spelling | doaj.art-5266f7573ba64d58a50f47f65153fc252022-12-21T21:17:34ZengPublic Health Agency of CanadaCanada Communicable Disease Report1481-85312020-02-01462/3363910.14745/ccdr.v46i23a03Summary of the NACI Statement on the Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B DiseaseRobyn Harrison0Robert Stirling1Oliver Baclic2Wendy Vaudry3NACI Meningococcal Disease Working Group Chair; University of Alberta, Edmonton, ABPublic Health Agency of Canada, Ottawa, ONPublic Health Agency of Canada, Ottawa, ONUniversity of Alberta, Edmonton, AB; NACI Meningococcal Disease Working Group past ChairBackground: Trumenba™, a bivalent, factor-H binding protein meningococcal serogroup B (MenB-fHBP) vaccine was authorized for use in Canada in October 2017 for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in individuals 10–25 years of age. The National Advisory Committee on Immunization (NACI) provides recommendations regarding the use of meningococcal vaccines to the Public Health Agency of Canada. Objective: To summarize NACI recommendations regarding the use of MenB-fHBP vaccine in Canada. Methods: The NACI Meningococcal Disease Working Group developed a predefined search strategy to identify all eligible studies, assessed the quality of these studies, and summarized and analyzed the findings. According to the NACI evidence-based process, the working group then proposed recommendations and identified the grade of evidence that supported them. In light of the evidence, the recommendations were then considered and approved by NACI. Results: The two serogroup B meningococcal vaccines currently authorized for use in Canada are not interchangeable as they contain different antigens and there are no published studies on the immunogenicity resulting from a vaccination series combining the two products. Following the review of evidence, NACI recommends that MenB-fHBP vaccine may be considered as an option for use in individuals 10 years of age and older in situations when a serogroup B meningococcal vaccine should be offered: 1) during serogroup B meningococcal disease outbreaks or with the emergence of hyperendemic N. meningitidis strains that are predicted to be susceptible to the vaccine; 2) for individuals who are close contacts with a case of invasive meningococcal disease caused by serogroup B N. meningitidis; 3) for individuals with underlying medical conditions that would put them at higher risk of meningococcal disease than the general population; or 4) for individuals at higher risk of exposure to serogroup B meningococcal isolates than the general population. NACI also recommends that MenB-fHBP vaccine may be considered as an option for individuals 10–25 years of age who are not at higher risk of meningococcal disease than the general population, but who wish to reduce their risk of invasive serogroup B meningococcal disease. Conclusion: NACI recommends immunization against serogroup B IMD for all individuals who are at a higher risk of disease due to an underlying medical condition or an increased risk of exposure. In addition to providing guidance to public health decision-makers (i.e. provinces/territories making decisions for publicly-funded immunization programs), these NACI recommendations provide information to individuals, vaccine providers and organizations about vaccines that may not currently be included in publicly funded immunization programs. NACI continues to recommend against the use of the serogroup B vaccines in routine universal immunization programs in Canada at this time.https://doi.org/10.14745/ccdr.v46i23a03national advisory committee on immunizationnaciimdmeningococcal vaccineguidance |
| spellingShingle | Robyn Harrison Robert Stirling Oliver Baclic Wendy Vaudry Summary of the NACI Statement on the Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease Canada Communicable Disease Report national advisory committee on immunization naci imd meningococcal vaccine guidance |
| title | Summary of the NACI Statement on the Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease |
| title_full | Summary of the NACI Statement on the Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease |
| title_fullStr | Summary of the NACI Statement on the Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease |
| title_full_unstemmed | Summary of the NACI Statement on the Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease |
| title_short | Summary of the NACI Statement on the Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease |
| title_sort | summary of the naci statement on the use of bivalent factor h binding protein meningococcal serogroup b menb fhbp vaccine for the prevention of meningococcal b disease |
| topic | national advisory committee on immunization naci imd meningococcal vaccine guidance |
| url | https://doi.org/10.14745/ccdr.v46i23a03 |
| work_keys_str_mv | AT robynharrison summaryofthenacistatementontheuseofbivalentfactorhbindingproteinmeningococcalserogroupbmenbfhbpvaccineforthepreventionofmeningococcalbdisease AT robertstirling summaryofthenacistatementontheuseofbivalentfactorhbindingproteinmeningococcalserogroupbmenbfhbpvaccineforthepreventionofmeningococcalbdisease AT oliverbaclic summaryofthenacistatementontheuseofbivalentfactorhbindingproteinmeningococcalserogroupbmenbfhbpvaccineforthepreventionofmeningococcalbdisease AT wendyvaudry summaryofthenacistatementontheuseofbivalentfactorhbindingproteinmeningococcalserogroupbmenbfhbpvaccineforthepreventionofmeningococcalbdisease |